% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • fribon fribon May 2, 1998 10:12 PM Flag

    huge increase in short interest


    Your right that VX-478 does
    not appear to stand above the other PI's in terms of
    efficacy and resistance. We'd still be above 40 if it did.

    There was worry about the skin rash issue which drove
    the stock back into the high 20's. That issue seemed
    to be resolved with the Phase II data at the last
    HIV conference.

    There are some factors which
    may win market share for VX-478 with time:

    Glaxo is the #1 marketer of anti-HIV therapy.

    VX-478 is given as a twice a day regimen as compared to
    3 times a day for other drugs.

    3) It is the
    only HIV drug I know of being tested for children. I
    don't think they've released any data.

    4) There
    was some indication in prior trials that VX-478
    crosses the blood brain barrier. If this is the case,
    VX-478 would be an important cocktail component,
    especially in patients with active viral

    5) It's being tested in various Cocktail combos,
    which means clinicians will know that it works with
    other drugs rather than have to find out empirically.
    (Eg: Glaxo is testing it with Abacavir, a new

    6) Clinical Study safety/tolerance data I don't
    think shed much light on what its like for a patient to
    be on the drug. The true test of VX-478 will be when
    patients start taking it and it builds a reputation
    (either good or bad with clinicians and

    Take Care,


109.46-5.06(-4.42%)Oct 6 4:00 PMEDT